Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma
NCT05961761Phase 2Recruiting
- Start
- Aug 2021
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of propranolol and pembrolizumab in angiosarcoma and undifferentiated pleomorphic sarcoma (UPS). Primary endpoint: Progression-Free Survival Rate at 3 months. Started Aug 2021; status: recruiting.
02
Drugs
propranololpembrolizumab
03
Conditions
angiosarcomaundifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT05961761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961761.